This trial is evaluating whether MRT Stability will improve 3 primary outcomes and 1 secondary outcome in patients with Prostate Cancer. Measurement will happen over the course of 8 weeks.
This trial requires 60 total participants across 1 different treatment group
This trial involves a single treatment. MRT Stability is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"In [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), definitive treatment and PSA surveillance alone were not associated with clinically significant change in time to prostatectomy, as well as the progression-free probability and overall survival. In a recent study, findings suggest that radical prostatectomy in lieu of watchful waiting may offer patients more favorable outcomes without delaying time to salvage therapy." - Anonymous Online Contributor
"Signs of prostate cancer can include unexplained fever, swollen or hard lymph nodes, persistent pain with urination or tiredness and difficulty starting to ejaculate. Other signs of prostate cancer include loss of semen and trouble starting to have sex.\n" - Anonymous Online Contributor
"Prostate cancer is a cancer that forms in the prostate and typically appears in men over the age of 50. It is often identified by frequent, painful or bloody urination or painful ejaculation. Prostate cancer affects about 1 in 3 men over the age of 50. It is one of the most significant causes of death from cancer in the developed world. Prostate cancer is one of the few cancers with a mortality rate more than fivefold higher among black than white men. The average age of diagnosis in the U.S. is 80, and in most developed countries it is much later. Prostate cancer is common, with the highest rates in the developed world, except for Western Australia, where prostate cancer occurs far more often than expected." - Anonymous Online Contributor
"Common treatments for prostate cancer include watchful waiting, minimally invasive forms of treatment, hormonal agents (androgen deprivation therapy) and radiation therapy. Immunotherapy has also been studied.\n" - Anonymous Online Contributor
"The prostate is not a cancer-prone organ. Instead, prostate cancer mainly arises because the prostate retains cells after a prostatectomy. Therefore, it is the removal or destruction of the prostate cells that leads to prostate cancer - and not an environmental risk factor." - Anonymous Online Contributor
"The data are interpreted to indicate that the incidence of prostate cancer in the general US population may be about equal to the incidence in Sweden. If an average of 0.9 cases for every 100,000 men was assumed, the overall incidence in the United States would be about 3.5 cases per 100,000 men." - Anonymous Online Contributor
"Findings from a recent study found that, in the general community, the only factor shown to be highly predictive of mrt metastatic relapse was stability on first treatment, whereas no other variable demonstrated the best outcome. Findings from a recent study suggest that stability of metastatic prostate cancer lesions on treatment is a promising potential outcome variable for metastatic prostate cancer treatment, although this must be confirmed in future, randomized studies." - Anonymous Online Contributor
"Results from a recent paper demonstrates for the first time that the stability of mrt is not affected by people with malignant mesothelioma. We therefore recommend that it can be safely administered to people with malignant mesothelioma." - Anonymous Online Contributor
"Previous mrt trials have generally observed relatively low efficacy compared to other cancer therapies. Despite its relatively limited efficacy, radiotherapy is still an effective treatment for selected, metastatic and locally advanced prostate cancer indications, where it is most often initiated as the sole treatment." - Anonymous Online Contributor
"While MR is still the mainstay for most people, with the improvements noted in equipment and scan protocols. This is a major step forward, both technical and from a therapeutic perspective." - Anonymous Online Contributor
"Most often prostate cancer is mild or moderately serious. To facilitate the discussion, the seriousness of prostate cancer was divided into mild, moderate, and severe with respect to the risk of dying within the first year after diagnosis or death at all. While there are patients with severe prostate cancer in whom cure by surgery is unlikely, the vast majority of patients do not die within a year of diagnosis and/or surgery." - Anonymous Online Contributor
"Results from a recent clinical trial demonstrate that patients receiving the MRT were as effective as placebo users with respect to symptom control and quality of life, while MRT showed no adverse effects in terms of QOL and symptom control. Although the results indicate MRT to be effective, several patient specific factors including age, education, and employment status affect outcomes. Further study is needed to validate the efficacy and safety of MRT." - Anonymous Online Contributor